Merck announces efficiency program across all businesses and regions

Merck KGaAMerck's Executive Board presented initial plans for an efficiency program spanning all businesses and regions to the Supervisory Board and relevant employee representative bodies. The planned efficiency measures are part of the Group's comprehensive transformation program, which was announced last year and consists of two phases: In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and develop a long-term growth strategy. In the second phase, the focus will be on exploiting new growth opportunities ahead.

"In its long history Merck has grown to be a successful, world-class company with strong positions in many of its key businesses," said Karl-Ludwig Kley, Chairman of the Executive Board. "Nevertheless over the next two years Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model. We will therefore progress with our planned efficiency program in order to deliver recurring cost reductions and free up resources for investment in promising growth areas.”

Kley added: "While it is regrettable, our preliminary analysis has shown that the overall purpose of our transformation program and the expected measures to realize it may lead to workforce reductions across all businesses and regions."

Paying tribute to the traditionally strong relationship with the employee representatives at Merck, the Group will now start the consultation processes with the respective employee representatives in different countries, with the intention to seek socially acceptable solutions where they are possible. Until the consultations are further advanced, it would be premature to announce any detailed cost or headcount reduction plans.

"We have a view on what needs to be achieved, but we will consult with the employee representatives on a country-by-country basis and we will consider any pragmatic proposals," Kley said. "We have specifically not published potential figures related to the efficiency program as we are committed to engaging constructively with the relevant stakeholders to achieve a mutually acceptable solution. This approach reflects the strong tradition of Merck."

At the beginning of 2012, Merck has started the implementation of a new leadership organization which defines the relationship of businesses, Group functions and country organizations. The objective of the new leadership organization is to streamline the organizational structure to be leaner, easier to navigate and to speed up decision-making processes. This realignment will continue in parallel to and support the efficiency program as well as the development of the Group's long-term growth strategy.

In the second phase of the transformation program, Merck will tap areas for future growth based on broader industry and macroeconomic trends. Initial work to explore these growth opportunities has already been started and Merck will further drive the development of its long-term growth strategy over the next two years. Merck is convinced that the ability to effectively implement any major strategic initiatives in the future will be predicated on successfully implementing the new leadership organization and completion of the efficiency program.

About Merck KGaA
Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...